| Nov 19 |
CNS Drug Development: Same As It Ever Was
|
| Oct 31 |
Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler
|
| Oct 30 |
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
|
| Oct 30 |
Biogen, Sage admit a defeat in major depression
|
| Oct 30 |
Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
|
| Oct 30 |
Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Transcript
|
| Oct 29 |
Sage Therapeutics, Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Oct 29 |
Sage stock plunges 18% post-market following business update, earnings
|
| Oct 29 |
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
|
| Oct 29 |
Sage Therapeutics GAAP EPS of -$1.53 beats by $0.02, revenue of $11M misses by $0.12M
|
